Retension Pharmaceuticals prices IPO at $12 per share on Nasdaq

🇺🇸 Investing.com (US) — 2026-10-09

Retension Pharmaceuticals priced its initial public offering at $12 per share on Nasdaq. The article provides no further details on the offering size or company operations.

Markets Deals Health Retension Pharmaceuticals IPO Nasdaq share pricing public offering biopharmaceuticals

Read original source →

Glaukos: The Second J-Code Rewrites The Risk Math
Seeking Alpha — 2026-10-10
'Let India play against themselves' - West Indies should stop playing to challenge ICC's revenue-sharing model, says former CWI President
Yahoo Sports — 2026-10-10
Midterm break
Dawn Pakistan — 2026-10-10
Sanctions des Etats-Unis contre la CPI : Washington lance un ultimatum aux Etats membres
Le Monde — 2026-10-10
No, not now! Why IMF is hesitant to commit other billions to Ruto's regime
The Standard Kenya — 2026-10-10
Banks, research institutions see Budget 2027 balancing growth, household support and fiscal discipline
Malay Mail — 2026-10-10

Retension Pharmaceuticals prices IPO at $12 per share on Nasdaq

AI Summary

Related Articles

Glaukos: The Second J-Code Rewrites The Risk Math

&#39;Let India play against themselves&#39; - West Indies should stop playing to challenge ICC&#39;s revenue-sharing model, says former CWI President

Midterm break

Sanctions des Etats-Unis contre la CPI : Washington lance un ultimatum aux Etats membres

No, not now! Why IMF is hesitant to commit other billions to Ruto's regime

Banks, research institutions see Budget 2027 balancing growth, household support and fiscal discipline

'Let India play against themselves' - West Indies should stop playing to challenge ICC's revenue-sharing model, says former CWI President